Q-omics provides the consensus-scored ERI1 profile across patient tissues and cancer cell-line models. ERI1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ERI1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ERI1 protein abundance shows 29,599 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where ERI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERI1 survival associations across molecular data types. ERI1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERI1 RNA expression–survival associations across cancer types. High ERI1 expression shows unfavorable associations in KIRP, KICH, LIHC, ACC, LGG and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ERI1 RNA expression.
This table summarizes ERI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ERI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERI1 shows higher tumor expression in HNSC, KIRP, STAD, LIHC, UCEC and BLCA. The HNSC box plot shows higher ERI1 RNA expression in tumor versus normal tissue (log2 FC = +0.588, t-test p < 0.001).
This table shows molecular features associated with ERI1 in patient tissues and cancer cell lines. In patient samples, ERI1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ERI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
